beta-D-FructopyranoseCAS# 7660-25-5 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 7660-25-5 | SDF | Download SDF |
| PubChem ID | 24310 | Appearance | Powder |
| Formula | C6H12O6 | M.Wt | 180 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | fructosteril;laevoral;laevosan | ||
| Solubility | H2O : 6.8 mg/mL (37.74 mM; Need ultrasonic and warming) | ||
| Chemical Name | (2R,3S,4R,5R)-2-(hydroxymethyl)oxane-2,3,4,5-tetrol | ||
| SMILES | C1C(C(C(C(O1)(CO)O)O)O)O | ||
| Standard InChIKey | LKDRXBCSQODPBY-ARQDHWQXSA-N | ||
| Standard InChI | InChI=1S/C6H12O6/c7-2-6(11)5(10)4(9)3(8)1-12-6/h3-5,7-11H,1-2H2/t3-,4-,5+,6-/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
beta-D-Fructopyranose Dilution Calculator
beta-D-Fructopyranose Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 5.5556 mL | 27.7778 mL | 55.5556 mL | 111.1111 mL | 138.8889 mL |
| 5 mM | 1.1111 mL | 5.5556 mL | 11.1111 mL | 22.2222 mL | 27.7778 mL |
| 10 mM | 0.5556 mL | 2.7778 mL | 5.5556 mL | 11.1111 mL | 13.8889 mL |
| 50 mM | 0.1111 mL | 0.5556 mL | 1.1111 mL | 2.2222 mL | 2.7778 mL |
| 100 mM | 0.0556 mL | 0.2778 mL | 0.5556 mL | 1.1111 mL | 1.3889 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Imidazo[1,2-b]pyridazine
Catalog No.:BCC9001
CAS No.:766-55-2
- 3-Ethyl-4-methyl-3-pyrrolin-2-one
Catalog No.:BCC8632
CAS No.:766-36-9
- OR-486
Catalog No.:BCC5661
CAS No.:7659-29-2
- Divalproex Sodium
Catalog No.:BCC4379
CAS No.:76584-70-8
- SR 202
Catalog No.:BCC7243
CAS No.:76541-72-5
- Heraclenol 3'-O-[beta-D-apiofuranosyl-(1-6)-beta-D-glucopyranoside]
Catalog No.:BCN1362
CAS No.:765316-44-7
- 1-2-Cyclohexanedione
Catalog No.:BCN2265
CAS No.:765-87-7
- 10-Hydroxy-2-decenoic acid
Catalog No.:BCN2654
CAS No.:765-01-5
- 15,16-Dinor-8(17),11-labdadien-13-one
Catalog No.:BCN4312
CAS No.:76497-69-3
- Ligustrazine Hydrochloride
Catalog No.:BCN1009
CAS No.:76494-51-4
- 8-Acetoxy-15,16-epoxy-8,9-secolabda-13(16),14-diene-7,9-dione
Catalog No.:BCN7409
CAS No.:76475-32-6
- Croverin
Catalog No.:BCN2518
CAS No.:76475-17-7
- BAM 22P
Catalog No.:BCC5797
CAS No.:76622-26-9
- Detomidine
Catalog No.:BCC4079
CAS No.:76631-46-4
- RU 26752
Catalog No.:BCC7531
CAS No.:76676-33-0
- RU 28318, potassium salt
Catalog No.:BCC7146
CAS No.:76676-34-1
- E-64-c
Catalog No.:BCC3588
CAS No.:76684-89-4
- 1-Deacetylnimbolinin B
Catalog No.:BCN4313
CAS No.:76689-98-0
- Mallorepine
Catalog No.:BCN4317
CAS No.:767-98-6
- Decumbenine
Catalog No.:BCC8312
CAS No.:76733-83-0
- Pyronaridine Tetraphosphate
Catalog No.:BCC1144
CAS No.:76748-86-2
- Lupalbigenin
Catalog No.:BCN4314
CAS No.:76754-24-0
- GBR 12935
Catalog No.:BCC5381
CAS No.:76778-22-8
- 2'-Hydroxydaidzein
Catalog No.:BCN4585
CAS No.:7678-85-5
High Fructose Intake During Pregnancy in Rats Influences the Maternal Microbiome and Gut Development in the Offspring.[Pubmed:29971089]
Front Genet. 2018 Jun 19;9:203.
Studies in pregnant women indicate the maternal microbiome changes during pregnancy so as to benefit the mother and fetus. In contrast, disruption of the maternal microbiota around birth can compromise normal bacterial colonisation of the infant's gastrointestinal tract. This may then inhibit development of the gut so as to increase susceptibility to inflammation and reduce barrier function. The impact of modulating fructose intake on the maternal microbiome through pregnancy is unknown, therefore we examined the effect of fructose supplementation on the maternal microbiome together with the immediate and next generation effects in the offspring. Wistar rat dams were divided into control and fructose fed groups that received 10% fructose in their drinking water from 8 weeks of age and throughout pregnancy (10-13 weeks). Maternal fecal and blood samples were collected pre-mating (9 weeks) and during early (gestational day 4-7) and late pregnancy (gestational day 19-21). We show supplementation of the maternal diet with fructose appears to significantly modulate the maternal microbiome, with a significant reduction in Lactobacillus and Bacteroides. In offspring maintained on this diet up to pregnancy and term there was a reduction in gene expression of markers of gut barrier function that could adversely affect its function. An exacerbated insulin response to pregnancy, reduced birth weight, but increased fat mass was also observed in these offspring. In conclusion dietary supplementation with fructose modulates the maternal microbiome in ways that could adversely affect fetal growth and later gut development.
